A detailed history of China Universal Asset Management Co., Ltd. transactions in Replimune Group, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 13,140 shares of REPL stock, worth $168,060. This represents 0.02% of its overall portfolio holdings.

Number of Shares
13,140
Previous 7,214 82.15%
Holding current value
$168,060
Previous $64,000 125.0%
% of portfolio
0.02%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$8.09 - $11.23 $47,941 - $66,548
5,926 Added 82.15%
13,140 $144,000
Q2 2024

Jul 19, 2024

SELL
$5.01 - $9.46 $23,015 - $43,459
-4,594 Reduced 38.91%
7,214 $64,000
Q1 2024

Apr 29, 2024

BUY
$6.87 - $9.31 $34,178 - $46,317
4,975 Added 72.81%
11,808 $96,000
Q4 2023

May 21, 2024

SELL
$6.75 - $16.18 $33,581 - $80,495
-4,975 Reduced 42.13%
6,833 $57,000
Q4 2023

Jan 23, 2024

BUY
$6.75 - $16.18 $35,937 - $86,142
5,324 Added 352.82%
6,833 $58,000
Q3 2023

May 21, 2024

BUY
$15.96 - $22.18 $12,001 - $16,679
752 Added 99.34%
1,509 $25,000
Q3 2023

Oct 30, 2023

BUY
$15.96 - $22.18 $12,001 - $16,679
752 Added 99.34%
1,509 $26,000
Q2 2023

May 21, 2024

SELL
$15.65 - $24.1 $172 - $265
-11 Reduced 1.43%
757 $17,000
Q2 2023

Jul 27, 2023

SELL
$15.65 - $24.1 $172 - $265
-11 Reduced 1.43%
757 $18,000
Q1 2023

May 21, 2024

BUY
$17.48 - $29.09 $4,597 - $7,650
263 Added 52.08%
768 $13,000
Q1 2023

Apr 27, 2023

BUY
$17.48 - $29.09 $4,597 - $7,650
263 Added 52.08%
768 $14,000
Q4 2022

May 21, 2024

SELL
$17.09 - $27.91 $193,168 - $315,466
-11,303 Reduced 95.72%
505 $13,000
Q4 2022

Jan 31, 2023

BUY
$17.09 - $27.91 $734 - $1,200
43 Added 9.31%
505 $14,000
Q3 2022

Oct 21, 2022

BUY
$15.6 - $21.15 $7,207 - $9,771
462 New
462 $8,000

Others Institutions Holding REPL

About Replimune Group, Inc.


  • Ticker REPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,306,700
  • Market Cap $631M
  • Description
  • Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...
More about REPL
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.